Experimental BioAge drug protected mouse retinas from geographic atrophy damage

Experimental BioAge drug protected mouse retinas from geographic atrophy damage

Biotech company BioAge tested an oral analog of its clinical compound BGE-102 in a mouse model of geographic atrophy, a late stage of age-related retinal degeneration that irreversibly destroys central vision. On 2 October 2026, at the EURETINA ophthalmology conference in Vienna, company scientist Aiden Ablimit presented data showing that the drug prevented toxic pigment accumulation in retinal cells, reduced damage from protein deposits, and preserved the cell layer that this disease destroys in humans. An independent congress publication confirmed the report.

Geographic atrophy develops when the retinal pigment epithelium dies. This thin cell layer nourishes and maintains the photoreceptors responsible for vision. Without it, photoreceptors degenerate and the patient irreversibly loses central vision. Two drugs approved in the US since 2023, pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay), block the complement system, a component of innate immunity, but require an injection into the eye every one to two months and only slow the growth of the lesion. In a 2026 survey of retinal specialists, lesion growth rate was the primary criterion for choosing a therapy.

BioAge identified the NLRP3 target from human longevity data: in people who age more slowly than their peers, this protein complex shows lower activity. NLRP3 is an intracellular danger sensor that triggers inflammation in response to damage. An oral NLRP3 inhibitor has already completed phase 1 in humans and is currently being evaluated in two phase 2 trials, one for cardiovascular risk and one for diabetic macular edema, another eye disease in which the same inflammatory pathway damages blood vessels.

For the geographic atrophy experiment, BioAge engineered mice carrying the human NLRP3 gene (the drug targets the human form of this protein and does not act on the mouse ortholog) and induced retinal damage with amyloid-beta oligomers, the same aggregated protein fragments that damage neurons in Alzheimer's disease. In humans with geographic atrophy, identical particles accumulate in drusen, yellow deposits beneath the retina, and poison the pigment epithelium: they disrupt its recycling of photoreceptor segments, causing the toxic pigment lipofuscin to build up, and simultaneously activate inflammation through the same NLRP3 complex. According to BioAge, the oral BGE-102 analog markedly reduced the volume of retinal damage in treated mice and substantially preserved pigment epithelium structure; the company did not disclose exact effect sizes. The competing gene therapy OCU410 slowed lesion growth by 31% over one year in phase 2, a result currently regarded as the benchmark in this field.

An independent congress report confirmed both findings and added that the drug also prevented lipofuscin accumulation. The same session featured 36-month data on the PRIMA implant, which restores vision through electrical stimulation of the retina and received CE marking for commercial sale in Europe in July, along with data from several gene therapies that deliver a new gene directly into the eye. Among all nine presentations in the session, BGE-102 was the only oral candidate; every other therapy requires injection into the eye or surgical implantation.

BGE-102, the same compound BioAge is already testing in humans for two other indications, demonstrated a protective effect in a geographic atrophy model for the first time.